Ranzhiqiang Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ranzhiqiang Yang has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Chuang Peng
Department of Hepatobiliary Surgery, Hunan Provincial People’s Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, People’s Republic of China
2 shared publications - Chunzhao Yu
Department of General Surgery, Sir Run Run Hospital, Nanjing Medical University, Nanjing, Jiangsu, China
2 shared publications - Jianing Yi
Department of General Surgery, Sir Run Run Hospital of Nanjing Medical University, 211166 Nanjing, Jiangsu, China
2 shared publications - Sulai Liu
Central Laboratory, Hunan Provincial People’s Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, China
2 shared publications - Wenjie Gao
Department of General Surgery, Sir Run Run Hospital of Nanjing Medical University, 211166 Nanjing, Jiangsu, China
2 shared publications - Yinghui Song
Central Laboratory, Hunan Provincial People’s Hospital/The First Affiliated Hospital of Hunan Normal University, Changsha, P. R. China
2 shared publications
Latest Publications
- Open Access
- 23 October 2026
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 31 (10)
Integrated Bioinformatic and Experimental Analyses Identify CNTN6 as a Tumor-Promoting Factor and Prognostic Biomarker in Hepatocellular Carcinoma
Background: Hepatocellular carcinoma (HCC) remains a highly lethal malignancy, and reliable biomarkers are needed for prognostic stratification and the development of therapeutic strategies. Contactin-6 (CNTN6), a member of the immunoglobulin superfamily of cell-adhesion molecules, has not been fully characterized in HCC. Methods: Public datasets were used to evaluate CNTN6 expression, clinicopathological associations, immune-cell infiltration, prognostic value, and correlations with drug sensitivity in HCC. The biological functions of CNTN6 were assessed using HCC cell lines and xenograft models with CNTN6 knockdown and overexpression. Results: CNTN6 was upregulated in HCC tissues and was associated with several clinicopathological features. Elevated CNTN6 expression was associated with poor survival outcomes and an M2-like macrophage infiltration signature. Functional enrichment analysis suggested that CNTN6-related proteins may participate in cell migration and oncogenic signaling pathways. In vitro, CNTN6 knockdown suppressed HCC cell proliferation, colony formation, migration, and invasion, whereas CNTN6 overexpression enhanced these malignant phenotypes. In vivo, CNTN6 knockdown reduced xenograft tumor growth and altered CD86/CD206 immunostaining patterns. Conclusions: CNTN6 is upregulated in HCC and may function as a tumor-promoting factor associated with poor prognosis and macrophage-related immune remodeling. Further mechanistic and clinical validation is warranted.
- 23 October 2026
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 31 (10)
Open AccessIntegrated Bioinformatic and Experimental Analyses Identify CNTN6 as a Tumor-Promoting Factor and Prognostic Biomarker in Hepatocellular Carcinoma
Background: Hepatocellular carcinoma (HCC) remains a highly lethal malignancy, and reliable biomarkers are needed for prognostic stratification and the development of therapeutic strategies. Contactin-6 (CNTN6), a member of the immunoglobulin superfamily of cell-adhesion molecules, has not been fully characterized in HCC. Methods: Public datasets were used to evaluate CNTN6 expression, clinicopathological associations, immune-cell infiltration, prognostic value, and correlations with drug sensitivity in HCC. The biological functions of CNTN6 were assessed using HCC cell lines and xenograft models with CNTN6 knockdown and overexpression. Results: CNTN6 was upregulated in HCC tissues and was associated with several clinicopathological features. Elevated CNTN6 expression was associated with poor survival outcomes and an M2-like macrophage infiltration signature. Functional enrichment analysis suggested that CNTN6-related proteins may participate in cell migration and oncogenic signaling pathways. In vitro, CNTN6 knockdown suppressed HCC cell proliferation, colony formation, migration, and invasion, whereas CNTN6 overexpression enhanced these malignant phenotypes. In vivo, CNTN6 knockdown reduced xenograft tumor growth and altered CD86/CD206 immunostaining patterns. Conclusions: CNTN6 is upregulated in HCC and may function as a tumor-promoting factor associated with poor prognosis and macrophage-related immune remodeling. Further mechanistic and clinical validation is warranted.
- 10 January 2025
- Published by Wiley in The FASEB Journal
- Vol. 39 (1) , e70300
A multidimensional pan‐cancer analysis of NDUFA4L2 and verification of the oncogenic value in colon cancer
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 4‐like 2 (NDUFA4L2) protein is located in the mitochondria and can regulate cell proliferation. Some studies have shown that the high NDUFA4L2 expression is linked with poor prognosis and cancer progression in various patients with cancers. However, the correlation between NDUFA4L2 and pan‐cancer is unknown. In this study, we used the databases and investigated the expression and variation of NDUFA4L2 in many cancers in detail to determine its diagnostic and prognostic values. We also validated the oncogenic capability of NDUFA4L2 in colon cancer by experiments or tissue microarray. In most cancers, NDUFA4L2 expression levels are upregulated, and a high level of NDUFA4L2 expression is associated with poor OS. In addition, the results showed that 10 proteins and 30 genes were correlated to NDUFA4L2 . An additional analysis demonstrated that these genes and proteins exhibited either negative or positive correlations with specific pathways. Moreover, we discovered that NDUFA4L2 expression was related to tumor stemness, MSI, TMB, immune cell infiltration and ROS production. Our results show that NDUFA4L2 affects the development and mitochondrial function of colon cancer cell lines. Finally, we identified that NDUFA4L2 was sensitive to 10 anticancer drugs. Our study suggest that NDUFA4L2 could serve as a prognostic and therapeutic biomarker for most cancer, including colon cancer.
- 10 January 2025
- Published by Wiley in The FASEB Journal
- Vol. 39 (1) , e70300
A multidimensional pan‐cancer analysis of NDUFA4L2 and verification of the oncogenic value in colon cancer
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 4‐like 2 (NDUFA4L2) protein is located in the mitochondria and can regulate cell proliferation. Some studies have shown that the high NDUFA4L2 expression is linked with poor prognosis and cancer progression in various patients with cancers. However, the correlation between NDUFA4L2 and pan‐cancer is unknown. In this study, we used the databases and investigated the expression and variation of NDUFA4L2 in many cancers in detail to determine its diagnostic and prognostic values. We also validated the oncogenic capability of NDUFA4L2 in colon cancer by experiments or tissue microarray. In most cancers, NDUFA4L2 expression levels are upregulated, and a high level of NDUFA4L2 expression is associated with poor OS. In addition, the results showed that 10 proteins and 30 genes were correlated to NDUFA4L2 . An additional analysis demonstrated that these genes and proteins exhibited either negative or positive correlations with specific pathways. Moreover, we discovered that NDUFA4L2 expression was related to tumor stemness, MSI, TMB, immune cell infiltration and ROS production. Our results show that NDUFA4L2 affects the development and mitochondrial function of colon cancer cell lines. Finally, we identified that NDUFA4L2 was sensitive to 10 anticancer drugs. Our study suggest that NDUFA4L2 could serve as a prognostic and therapeutic biomarker for most cancer, including colon cancer.
- Open Access
- 1 August 2023
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 9 (Supplement) , 50
Unraveling the heterogeneity of intercellular crosstalk in intrahepatic and extrahepatic cholangiocarcinoma using single-cell and spatial transcriptome profiling.
- 1 August 2023
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 9 (Supplement) , 50
Open AccessUnraveling the heterogeneity of intercellular crosstalk in intrahepatic and extrahepatic cholangiocarcinoma using single-cell and spatial transcriptome profiling.
- 1 January 2023
- Published by World Scientific Pub Co Pte Ltd in The American Journal of Chinese Medicine
- Vol. 51 (06) , 1613-1614
ERRATUM: Quercetin Inhibits Intrahepatic Cholangiocarcinoma by Inducing Ferroptosis and Inhibiting Invasion via the NF-κB Pathway
- 1 January 2023
- Published by World Scientific Pub Co Pte Ltd in The American Journal of Chinese Medicine
- Vol. 51 (06) , 1613-1614
ERRATUM: Quercetin Inhibits Intrahepatic Cholangiocarcinoma by Inducing Ferroptosis and Inhibiting Invasion via the NF-κB Pathway